First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

MLA

Gerald Falchook, et al. “First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of First-in-Class Fatty Acid Synthase Inhibitor TVB-2640 Alone and with a Taxane in Advanced Tumors.” EClinicalMedicine, vol. 34, no. 100797-, Apr. 2021. EBSCOhost, https://doi.org/10.1016/j.eclinm.2021.100797.

APA

Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur Frankel, Peter Schmid, Kathleen Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, & Howard Burris. (2021). First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine, 34(100797-). https://doi.org/10.1016/j.eclinm.2021.100797

Chicago

Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, et al. 2021. “First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of First-in-Class Fatty Acid Synthase Inhibitor TVB-2640 Alone and with a Taxane in Advanced Tumors.” EClinicalMedicine 34 (100797-). doi:10.1016/j.eclinm.2021.100797.